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ABSTRACT
BACKGROUND AND PURPOSE: Endoluminal reconstruction with ﬂow-diverting stents represents a widely accepted technique for the
treatment of complex intracranial aneurysms. This European registry study analyzed the initial experience of 15 neurovascular centers with
the Flow-Redirection Intraluminal Device (FRED) system.
MATERIALS ANDMETHODS: Consecutive patients with intracranial aneurysms treated with the FRED between February 2012 andMarch
2015 were retrospectively reviewed. Complications and adverse events, transient and permanent morbidity, mortality, and occlusion rates
were evaluated.
RESULTS: During the deﬁned study period, 579 aneurysms in 531 patients (median age, 54 years; range, 13–86 years) were treated with the
FRED. Seven percent of patients were treated in the acute phase (3 days) of aneurysm rupture. The median aneurysm size was 7.6 mm
(range, 1–36.6 mm), and the median neck size 4.5 mm (range, 1–30 mm). Angiographic follow-up of3 months was available for 516 (89.1%)
aneurysms. There was progressive occlusion witnessed with time, with complete occlusion in 18 (20%) aneurysms followed for up to 90
14 days, 141 (82.5%) for 180  20 days, 116 (91.3%) for 1 year  24 days, and 122 (95.3%) aneurysms followed for 1 year. Transient and
permanent morbidity occurred in 3.2% and 0.8% of procedures, respectively. The overall mortality rate was 1.5%.
CONCLUSIONS: This retrospective study in real-world patients demonstrated the safety and efﬁcacy of the FRED for the treatment of
intracranial aneurysms. In most cases, treatment with a single FRED resulted in complete angiographic occlusion at 1 year.
ABBREVIATIONS: ASPIRe  Aneurysm Study of Pipeline in an Observational Registry; EuFRED  European Flow-Redirection Intraluminal Device Study; FRED 
Flow-Redirection Intraluminal Device; PUFS Pipeline for Uncoilable or Failed Aneurysms Study
Flow diversion has become a widely accepted treatment optionfor all kinds of intracranial aneurysms, especially those with a
wide neck.1High rates of complete aneurysmocclusion have been
reported in a number of studies, even for large and giant aneu-
rysms.2 Since the inception of the flow-diversion concept, a num-
ber of different flow diverters with variations in stent design have
been developed and received Conformite´ Europe´ene or/and FDA
approval. Large multicenter cohort studies using 1 of those flow
diverters, the Flow-Redirection Endoluminal Device (FRED;
MicroVention, Tustin, California), are currently lacking. The de-
vice has a paired, integrated dual-layer self-expanding nitinol
braided design with an inner low-porosity stent that acts as the
flow diverter and an outer part that serves as a scaffold for the
inner stent. This dual-layer design is unique among currently
available flow-diverting stents. The Pivotal Study of the FRED
Stent System in the Treatment of Intracranial Aneurysms3 is a
current trial in the United States with results expected to be pub-
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lished in 2018. Here, we report the results of the European FRED
study (EuFRED), which included 15 European neurovascular
centers and evaluated the safety and efficacy of this device in con-
secutive real-world patients with intracranial aneurysms treated
with the FRED.
MATERIALS AND METHODS
Statement of Ethics
Local ethics committees acknowledged this study and the cor-
rect use of the patient data. All patients signed consent forms
approved by the institutional review boards or the ethics
committees.
Study Design
The EuFREDwas a retrospective,multicenter postmarket registry
of consecutive patients with intracranial aneurysms treated with
the FREDbetween February 2012 andMarch 2015 at 15 European
high-volume neurovascular centers with experienced neurointer-
ventionalists. Centers had to commit to contribute at least 5, pref-
erentially consecutive, cases. The decision to use the FRED was at
the discretion of the treating neurointerventionalist to reflect ap-
plication to real-world patients. Patients were eligible for enroll-
ment in the study under the following conditions: 1) They con-
sented to be treated with the FRED flow-diverting device; 2) they
met the requirements for FRED treatment per the instructions
for use approved for the country in which the patients were
treated; and 3) the center agreed to collect data of all consecu-
tive patients. The principal investigator (M.K.-O.) and a steer-
ing committee (C.J.G., B.M.) supervised the study design and
operations. This study was not funded by an industrial or gov-
ernmental source. Some of the patients in the present retro-
spective dataset were included in previously published single-
center case series.4-6
Data Collection
All centers used the same preprinted data-collection sheets, which
specified the data to be collected, study end points, and events of
interest. An independent study nurse collected all raw data, and
an independent statistician performed statistical analysis. Both
were not involved in clinical decision-making. The baseline infor-
mation studied included demographics, medical history, and an-
eurysm characteristics. The treatment characteristics collected in-
cluded the number and size of FREDs and parent vessels,
concomitant coil embolization, procedure duration, and use of
balloon angioplasty. Clinical and imaging follow-up time points
were at the discretion of the center. The clinical condition of pa-
tients was recorded according to themodified Rankin Scale score.
Follow-up intervals were defined as follows: 1) baseline (before
interventional treatment), 2) posttreatment (immediately after
the procedure), 3) minimum follow-up (90 days), 4) short-term
follow-up (90–180 days after the procedure), 5) midterm fol-
low-up (180–365 days after the procedure), and 6) long-term
follow-up (1 year). Vascular imaging was evaluated in the treat-
ing center by an independent neuroradiologist who was not in-
volved in the procedure. Digital subtraction angiography or
conebeam CT or both with intravenous contrast administration
was performed by 1 year. The technique for subsequent neurovas-
cular imaging was at the discretion of the individual center. An-
eurysm occlusion grade, in-stent stenosis, and device migration
were assessed. Aneurysm occlusion was assessed using a 3-point
Raymond-Roy scale and the O’Kelly-Marotta grading scale.7
In-stent stenosis was calculated on the basis of the minimal
luminal diameter and graded as mild (50%), moderate (50
to75%), or severe (75%). Device migration was defined as
the movement of the device 5 mm from its originally de-
ployed location.
All complications and adverse events from the time of treat-
ment to last follow-up were registered. The following complica-
tionswere specifically collected on the data sheets: 1) spontaneous
rupture of the FRED-treated aneurysm, 2) spontaneous nonan-
eurysmal intracranial hemorrhage ipsilateral or contralateral to
the treated aneurysm, 3) symptomatic ischemic stroke, 4) stent/
parent artery stenosis, 5) stent/parent artery occlusion, 6) perma-
nent cranial neuropathy, and 7) other complications that had to
be described. Neurologic symptoms due to a stroke were defined
as minor if the symptoms resolved within 1 month and major if
the patient experienced a clinical deficit for 1 month. An ad-
verse event was defined as any procedure-related event that re-
sulted in unexpected difficulties without any decline of the pa-
tient’s baseline neurologic status. Overall morbidity was defined
as transient if the clinical sequelae of the complication resolved
within 90 days and otherwise as permanent. Mortality was also
recorded.
Flow-Redirection Endoluminal Device
The FRED is a flow-diverter stent that was released for clinical use
in 2012. It has a paired, integrated dual-layer (stent-within-a-
stent) self-expanding nitinol braided design. The inner part of 48
braided nitinol wires determines the working length. It is a low-
porosity stent and acts as the active flow-diverting segment at the
neck region of the aneurysm, particularly at the inflow zone. The
outer part, which determines the total length, is a high-porosity
stent with 16 wires, serving as a scaffold for the inner stent. The
outer stent is 3 mm longer than the inner flow-diverter mesh at
each end so that these proximal and distal parts of the FRED can
be used to cover the adjacent perforating arteries or side branches
of the parent vessel.
Technique
All elective patients were pretreated with dual-antiplatelet medi-
cation or, in acute cases, individually according to the practices of
the hospitals. All patients were treated under general anesthesia
and followed for 24 hours after the procedure in an intensive care
unit. Procedures were performed through a 6F–8F femoral artery
access. A guiding-catheter system was placed into the distal cervi-
cal segment of the vessel leading to the intracranial vessel targeted
for treatment. A standard 0.027-inch ID microcatheter was then
manipulated over a 0.014- to 0.018-inch outer diameter mi-
crowire into position across the aneurysmneck.When coilingwas
to be performed in conjunction with FRED treatment, a standard
microcatheter was navigated into the aneurysm alongside the
0.027-inch microcatheter within the parent artery in a jailing
technique.Once the 0.027-inchmicrocatheterwas positioneddis-
tal to the aneurysm, the FRED was loaded via a rotating hemo-
842 Killer-Oberpfalzer May 2018 www.ajnr.org
static valve into the hub of the microcatheter and advanced with
the delivery wire. The device was then deployed across the tar-
geted landing zone through a process of microcatheter unsheath-
ing and delivery-wire stabilization/advancement. After delivery of
approximately two-thirds of the stent length, stent placement was
assessed and, if necessary, the stent was resheathed and released
again. Once deployed, if coil embolization was to be performed,
coils were deployed within the aneurysm through the jailed
microcatheter. Following coil embolization, the coiling micro-
catheter was gently removed from the aneurysm without dis-
placing the construct. Digital subtraction angiography was
performed to assess stent placement and the aneurysm occlu-
sion rate immediately after the procedure. Patients continued
antiplatelet therapy according to the standard of care in the
respective hospital.
Statistical Analysis
All statistical analyses were performed using SigmaPlot 13 (Systat
Software, San Jose, California). Data analysis was based on the
patient level, except for aneurysm and procedure characteristics,
which were based on the number of aneurysms and procedures,
respectively. Values are expressed as percentages. Numbers in pa-
rentheses are given for better understanding if indicated. Descrip-
tive statistics were used to present the data and summarize the
results. Discrete variables are presented using frequency distribu-
tions and cross-tabulations. Continuous variables are summa-
rized by presenting the number of observations, median, and
range of minimum andmaximum values. For correlation of nor-
mally distributed variables, the Pearson Product Moment Corre-
lation was used; otherwise, the nonparametric Spearman rank
order correlation was used. To indicate the strength and dire-
ction of the linear relationship between anterior/posterior circu-
lation aneurysms and transient morbidity, as well as the final oc-
clusion rate, and between aneurysm size and mortality and final
occlusion rate, we performed linear regression analysis. For infer-
ential statistics, data were analyzed by either the Student t test,
Fisher exact test,Mann-Whitney rank sum test, or Kruskal-Wallis
1-way analysis of variance on ranks (if not normally distributed,
the Shapiro-Wilk test). For pair-wisemultiple comparison proce-
dures, the Dunn method was used. All comparisons of variables
were performed at a significance level of .05 or .01 () and a power
of 0.80 ().
RESULTS
Baseline Patient and Aneurysm Characteristics
A total of 531 patients with 579 aneurysms were enrolled. The
median age was 54 years (range, 13–86 years), and 384 (72.3%)
patients were female. In 46.9% of patients, the aneurysm was an
incidental finding. Headache was the presenting symptom in
18.4% of patients, and 7% had a cranial nerve palsy. In 10.9%,
recanalization of a previously treated aneurysm was the indica-
tion for treatment. In 3.8% of patients, a stroke was the reason for
diagnosis, while subarachnoid hemorrhage occurred in 12.2%;
7.7% were treated in the acute phase with subarachnoid hemor-
rhage. Multiple aneurysms were reported in 26.6% of patients
(median number of aneurysms per patient, 1; range, 1–5). Not all
those aneurysms were treated with the FRED. The median aneu-
rysm sizewas 7.6mm(range, 1–36.6mm). Small (10mm), large
(10–20 mm), and giant (20 mm) aneurysms were encountered
in 76.9%, 17.4%, and 5.7%, respectively. The median aneurysm
neck diameter was 4.5mm (range, 1–30mm). Themedian dome-
to-neck ratio was 1.4. In 3.8% of aneurysms, partial thrombosis
was seen. Aneurysm morphology showed sidewall and bifurca-
tion aneurysms in 79.2% and 10.9%, respectively. In terms of
aneurysm location, 86.7% were in the anterior circulation, with
most in the internal carotid artery (Table 1).
Table 1: Baseline characteristics
Characteristics
No. of aneurysms 579
No. of patients 531
No. of procedures 534
Patient demographics
Male (No.) 147 (27.7%)
Female (No.) 384 (72.3%)
Age at time of treatment (median) (range) (yr) 54 (13–86)
Presentation of patients (No.)
Incidental 249 (46.9%)
Headaches 98 (18.4%)
Cranial nerve palsy 37 (7%)
Recanalization of previously treated aneurysm 58 (10.9%)
Subarachnoid hemorrhage 65 (12.2%)
Acute (3 days) 41 (7.7%)
Stroke 20 (3.8%)
Other 4 (0.8%)
Patients with multiple aneurysms (No.) 141 (26.6%)
Aneurysms per patient (median) (range) 1 (1–5)
Patients with a single aneurysm 390 (73.5%)
Patients with 2 aneurysms 101 (19%)
Patients with 3 aneurysms 30 (5.7%)
Patients with 4 aneurysms 8 (1.5%)
Patients with 5 aneurysms 2 (0.3%)
Pretreatment mRS (per patient) (No.)
0–2 525 (98.8%)
3–5 6 (1.2%)
Aneurysm characteristics (No.)
Left 272 (47.0%)
Right 257 (44.4%)
Midline 50 (8.6%)
Anterior circulation (No.)
Internal carotid artery
Posterior communicating 50 (8.6%)
Paraophthalmic 270 (46.6%)
Cavernous 45 (7.8%)
Other 67 (11.5%)
Middle cerebral artery 37 (6.4%)
Anterior cerebral artery 16 (2.7%)
Anterior communicating artery 4 (0.9%)
Pericallosal artery 13 (2.2%)
Posterior circulation (No.) 36 (6.2%)
Basilar artery 30 (5.2%)
Posterior cerebral artery 9 (1.6%)
Superior cerebellar artery 2 (0.3%)
Aneurysm morphology (No.)
Saccular
Sidewall 459 (79.2%)
Bifurcation 63 (10.9%)
Fusiform/dissecting/blister
Fusiform 27 (4.7%)
Dissecting 20 (3.5%)
Blister 10 (1.7%)
Maximal diameter (median) (range) (mm) 7.6 (1–36.6)
Neck diameter (median) (range) (mm) 4.5 (1–30)
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Treatment Characteristics
Platelet-function testing was performed in 62.7% of procedures.
A combination of aspirin and clopidogrel was the most common
dual-antiplatelet regimen (92.1%). The duration of dual-anti-
platelet therapy varied among centers from 1 month to 1 year. A
total 579 aneurysms in 531 patients were treated in 534 proce-
dures using a median of 1 FRED (range, 1–5). In 515 procedures
(96.4%), a single FREDwas used. In 5 procedures, the initial stent
shortened more than expected and a second stent was placed. In
10 procedures, a second stent was intentionally used because lon-
ger stent sizes were not available at the time of the procedure. In 2
procedures, fusiform aneurysms needed 3 and 5 telescoping
stents, respectively. Two procedures were for retreatment. Stent
deployment was successful on first attempt in 98.3% of single
FRED procedures. In 17.6% of aneurysms, concomitant aneu-
rysm coiling was performed. In 15 (2.8%) procedures, balloon
angioplasty was performed, 5 of those being intentional in the
absence of poor opening. The procedure time was defined from
groin puncture to last angiogram andwas recorded at amedian of
65 minutes (range, 12–536 minutes) (On-line Table).
Adverse Events and Complications
A total of 75 (14%) complications and adverse events were re-
corded. Of those, 39 (7.3%) adverse events and complications
were reported in the periprocedural and 36 (6.7%) in the fol-
low-up period. There were 3 nonaneurysmal intracranial hemor-
rhages. One major hemorrhage on the ipsilateral side of the
treated aneurysm was detected on CT the day of the procedure
after sudden neurologic deterioration. Digital subtraction an-
giography andMR imaging showed stent and parent artery occlu-
sion and a major infarct with hemor-
rhagic transformation. This patient
died. There were 2 other nonaneurysmal
hemorrhages reported from wire perfo-
rations during stent delivery, one with-
out neurologic deterioration and one re-
sulting in a slight transient monoparesis
of the arm. Eight patients had a minor
stroke postoperatively, but symptoms
resolved within 1 month. During fol-
low-up, 1 growing aneurysm resulted in
a rupture 233 days after the procedure
anddeath of the patient, and another pa-
tient died due to unexpected aneurysm
rupture 1 week after the confirmation of
aneurysm occlusion at 1 month. There
were 3 reports of in-stent stenosis (all
50%) on follow-up. None of the cases
of in-stent stenosis were symptomatic
and needed treatment. In 12 procedures,
complete occlusion of the stent, parent
artery, and aneurysm complex was reg-
istered periprocedurally and during fol-
low-up. Ten of those were asymptom-
atic. One patient treated for an internal
carotid artery communicating segment
aneurysm showed a minor infarct on
MR imaging. Only 1 stent occlusion
caused the death of a patient. After routine follow-up at 6months,
a paraophthalmic aneurysm and parent artery showed complete
occlusion and the antiplatelet medication was stopped. One
month later the patient died from a severe stroke caused by stent
occlusion.
Two aneurysms showed enlargement with time. The regrowth
of a basilar trunk aneurysm caused brain stem compression. The
aneurysm was retreated 2 months later with a Pipeline Emboliza-
tion Device (Covidien, Irvine, California). The other aneurysm, a
fusiform M1 aneurysm treated with 2 telescopic stents, was un-
changed in terms of flow and showed slight growth after 9
months. At that time, a decision against retreatment was made
and the antiplateletmedicationwas stopped. Therewas no change
at 1-year follow-up.Clinical outcome at amedian follow-upof 6.6
months was favorable. While 515 patients had a good outcome
(mRS 0–2), 8 patients had a poor outcome (mRS 3–5) and an-
other 8 patients died (mRS 6). In univariable analysis, posterior
circulation location was associated with transient morbidity (P
.001), and aneurysms of20 mm were associated with mortality
(P .047). In multivariable analysis, posterior circulation aneu-
rysm was associated with transient morbidity (OR 3.661; 95%
CI, 1.685–7.953; P .001) (Table 2).
Imaging Outcomes
After a median follow-up time of 6.6 months (range, 0.03–45.6
months), the overall complete occlusion rate was 69.2%. The
number of aneurysms followed for 3 months was 516 (89.1%)
aneurysms. There was progressive occlusion witnessed across
time, with complete occlusion in 18 (20%) aneurysms followed
Table 2: Complications and adverse events per procedure
Periprocedural
(In-Hospital
Stay) (No.)
During Follow-Up
(after Hospital
Discharge) (No.)
Complications
Spontaneous rupture of the FRED-treated
aneurysm
0 2
Spontaneous nonaneurysmal intracranial
hemorrhage
3 1
Symptomatic ischemic stroke
Minor (1 mo) 8 5
Major (1 mo) 2 1
Stent/parent artery stenosis 5 3
Stent/parent artery occlusion 4 8
Permanent cranial neuropathy 0 0
Other complications
Groin hematoma 1
Dissection 1
Aneurysm growth 2
Total 24 (4.5%) 22 (4.1%)
Adverse events
Detachment in the hub of the microcatheter 2
Poor opening on deployment 10
Torquing of stent on deployment 1
Multiple repositioning 2
Visible gap between inner and outer stent 1
Fish mouthing of the distal stent end 13
Total 15 (2.8%) 14 (2.6%)
Transient morbidity (90 days) 10 (1.9%) 7 (1.3%)
Permanent morbidity (90 days) 3 (0.6%) 1 (0.2%)
Mortality 4 (0.75%) 4 (0.75%)
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for up to 90  14 days, 141 (82.5%) for 180  20 days, 116
(91.3%) for 1 year  24 days, and 122 (95.3%) aneurysms fol-
lowed for1 year. The overall aneurysm retreatment rate (using
the FRED or alternative techniques and devices) was 1.2%. In
univariable analysis, aneurysms of20 mmwere associated with
incomplete occlusion using the O’Kelly-Marotta grading scale.
No significant predictors of aneurysm occlusion were identified
in multivariable analysis.
DISCUSSION
The EuFRED is the largest study to date to evaluate the safety and
efficacy of the dual-layer flow-diverting stent, FRED. Fifteen Euro-
pean neurovascular centers contributed 531 patients with 579 aneu-
rysms treated in 534 procedures during 3 years. Any aneurysm
deemed suitable for FREDby the treatingneurointerventionalistwas
eligible. The study included a wide variety of aneurysms as encoun-
tered in the real-world patient population. Transient andpermanent
morbidity occurred in 3.2% and 0.8%, respectively, of procedures.
The overall mortality rate was 1.5%. Complete occlusion was
achieved in 95.3% of aneurysms followed for1 year.
Aneurysm Characteristics in EuFRED
Flow diversion has clearly revolutionized the endovascular treat-
ment of aneurysms. The 2 main principles on which the concept
was founded are diversion of blood flow away from the aneurysm
inducing stasis and thrombosis within the aneurysm sac and en-
dothelialization along the stent scaffold and restoration of the
integrity of the arterial wall.8 These devices have effectively ad-
dressed the issue of recanalization and the need for retreatment
associated with other endovascular treatment modalities and are
continuously gaining popularity among neurointerventionalists.9
Whereas treatment of internal carotid artery aneurysms up to the
superior hypophyseal segment provided an early experience with
flow diverters,1 use has since expanded to a number of different
aneurysm locations. In the EuFRED, 12.2% of aneurysms treated
were in the anterior circulation distal to the internal carotid ar-
tery, and 13.3%, in the posterior circulation. Thus, more than
one-quarter of aneurysms were located outside traditional loca-
tions, which mirrors a trend in the literature on flow diversion
that advocates its use further distal in the cerebrovascular tree at
or beyond the circle of Willis.10-12 While approximately one-
quarter of aneurysms in the EuFRED were large and giant and
deemed too difficult to treat using traditional endovascular tech-
niques, the median aneurysm diameter of 7.6 mm is a testament
that flow diversion may be suitable for aneurysms traditionally
managed with coil embolization with or without assist devices
such as stents or balloons.13
Along those lines are also the results of a matched analysis
comparing flow diversion with coiling of small and uncompli-
cated aneurysms, demonstrating a potential benefit for the flow
diverter even in simple lesions.14 The 41 (7.7%) aneurysms in the
EuFRED treated in acute aneurysmal subarachnoid hemorrhage
constitute another important aspect. Nevertheless, the potential
risk of rerupture due to a delay in aneurysm occlusion and the
need for dual-antiplatelet agents in an acute hemorrhage remain
challenges for this indication.15 There were 63 bifurcation aneu-
rysms treated in 62 patients with a medianmaximal diameter of 7
mm. Two of those aneurysms were treated in the acute phase of
subarachnoid hemorrhage. Likewise, 10 blister aneurysms were
treated in the setting of subarachnoid hemorrhage, 8 in the acute
phase and 1 each at 1 week and 1 month. In cases of blister aneu-
rysms treated in the acute phase, the patients were loaded with
tirofiban and later transitioned to aspirin and clopidogrel.
Aneurysm Occlusion after FRED
The overall rate of complete aneurysm obliteration in EuFRED
was 69.2%, with a progressive increase in the proportion of aneu-
rysms occluded with the duration of follow-up. Of aneurysms
followed for1 year, 95.3% were completely occluded. This ob-
servation is in line with prior studies that showed progressive
aneurysm obliteration after flow diversion. In the Pipeline for
Uncoilable or Failed Aneurysms (PUFS) trial, the rate of com-
pletely occluded aneurysms at 1 year was 86.8%1 and climbed to
93.4% at 3 years and 95.2% at 5 years.16,17 Aneurysms in PUFS,
however, were notably larger at a median aneurysm diameter of
17.5 mm compared with 7.6 mm in the EuFRED. Aneurysms of
20mmwere also associated with a lower rate of occlusion in the
EuFRED.Thenotion that aneurysm size is an important predictor
of aneurysm occlusion is also supported by a large multicenter
retrospective study of 380 aneurysms treated with Pipeline embo-
lization.18 In that study, the median aneurysm diameter was 7.7
mm, comparable with that in EuFRED, and the complete occlu-
sion rate in aneurysms followed for at least 1 year was 83.9%. The
study also included 13.4% of aneurysms located in the posterior
circulation. Both this study and EuFRED found that posterior
circulation aneurysms were less likely to occlude compared with
their anterior circulation counterparts on univariable analysis.
The studies were also comparable regarding the number of flow
diverters used.Whilemultiple devices were used in 98.1%of cases
in PUFS,17 most aneurysms in the EuFRED and the aforemen-
tioned multicenter study were treated with a single device.
Another study to serve as a reference is the prospective Aneu-
rysm Study of Pipeline in an Observational Registry (ASPIRe).19
Most aneurysms were also treated with a single device, but aneu-
rysms in ASPIRe were larger than in EuFRED at a median diam-
eter of 12 mm. Complete occlusion rates at 6 months and 1 year
were 78.6% and 78.9%, respectively.17 Similar to EuFRED, size
and location criteria followed country-specific instructions for
use. ASPIRe also included aneurysms in the posterior circula-
tion.19 The questions of whether occlusion rates using the FRED
are indeed superior to those of other flow diverters such as Pipe-
line remains unanswered in the absence of a well-designed direct
comparison study. Of the bifurcation aneurysms treated in
EuFRED, there was progressive occlusion with time that pla-
teaued at 1 year. Complete occlusion was noted in 38.1% at 90
days, 61.5% at 180 days, 88.8% at 1 year, and 85.7% at 1 year
from treatment. Of the blister aneurysms, 100% were completely
occluded at 3 months.
Adverse Events and Complications with FRED
In EuFRED, transient andpermanentmorbidity occurred in 3.2%
and 0.8% of procedures, respectively, with an overall mortality
rate of 1.5%. A pooled analysis of PUFS, ASPIRe, and the Inter-
national Retrospective Study of the Pipeline EmbolizationDevice,
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a retrospective study designed to assess safety-related outcomes,
reported major neurologic morbidity frommajor ipsilateral isch-
emic stroke and intracranial hemorrhage in 5.7% of patients. The
combinedmajor neurologic morbidity andmortality was 7.1%.17
A meta-analysis including 1654 Pipeline-treated aneurysms and
aneurysms treated with the Silk flow diverter (Balt Extrusion,
Montmorency, France) reported procedure-related morbidity
and mortality rates of 5% and 4%, respectively. Ischemic stroke
and perforator infarction rates were significantly higher in the
posterior compared with the anterior circulation. Large and giant
aneurysms had higher odds of ischemic stroke and subarachnoid
hemorrhage.20 Similar relationships were also detected in Eu-
FRED, inwhich transientmorbidity was associatedwith posterior
circulation location and mortality with aneurysms of 20 mm.
Of the bifurcation aneurysms treated, 1 patient had a major ipsi-
lateral hemorrhage the day of the procedure. Digital subtraction
angiography and MR imaging showed stent and parent artery
occlusion resulting in a major infarct with hemorrhagic transfor-
mation and death. Except for this patient, all other patients had at
least 90 days of follow-up and an mRS score between 0 and 2.
Among the patients with blister aneurysms, all had an mRS score
between 0 and 1 at last follow-up.
Strengths and Limitations
The main limitation of the present study is selection bias across the
different neurovascular centers and individual neurovascular practi-
tioners. No patient- and aneurysm-specific inclusion and exclusion
criteria were provided, tomirror the real world. Likewise, periproce-
dural and follow-up management was at the discretion of the insti-
tution, reflected in variations in platelet-function testing, antiplatelet
therapy, use of adjunctive coiling, and imaging follow-up schedule.
While patients were prospectively enrolled, data collection was ret-
rospective and subject to incomplete datasets. Data collection was
performed at the individual institution and not at a central location,
a core lab, introducing potential bias. The inclusion of multiple in-
stitutions, however, improved the generalizability of the findings.
While participating practitioners were encouraged to enroll consec-
utive cases, it is possible that alternative flow diverters were used
occasionally during the study period.
CONCLUSIONS
The EuFRED is the largest study to date assessing the safety and
efficacy of the FRED flow-diverting stent. Applied to whatmay be
considered a real-world patient population, FRED performed fa-
vorably regarding aneurysm obliteration and complications.
Well-designed studies comparing FREDwith other flow diverters
are required to substantiate those observations.
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